OLEG I. KRIJANOVSKI, M.D., Ph.D.
Alta Bates Summit Comprehensive Cancer Center
2001 Dwight Way
Berkeley, CA 94704
(510) 204-0644

Education and Training

07/1985 M.D. 2nd Moscow Medical Institute/Russian State/Pirogov, Russian State Medical
University, Russia
06/1994 Ph.D. Medical Science, Pediatric Hematology/Oncology Dissertation: “The Role of the Hematopoietic Stromal Microenvironment in Pathogenesis of Congenital Bone Marrow Failure Syndromes in Children.”
Research Institute of Pediatric Hematology of Russia, Moscow; Medical Science, Pediatric Hematology/Oncology.
09/1985 – 08/1987 Residency in Pediatrics, Moscow City Children’s Hospital #9, Moscow,
Russia
03/1990 – 02/1991 Gigax-Foundation Fellowship in Pediatric Hematology/Oncology and
Bone Marrow Transplantation, St. Anna Kinderspital, Vienna, Austria
08/1995 – 07/1999 Post-Doctoral Research Fellow, Pediatric Oncology Department, Dana
Farber Cancer Institute, Boston, MA
07/1999 – 07/2001 Resident in Pathology (Hematopathology & Blood Banking, Anatomic &
Clinical Pathology), Department of Pathology, University of Michigan,
Ann Arbor, MI
07/2001 – 07/2003 Residency in Internal Medicine (Clinical Investigator Pathway),
Department of Internal Medicine, University of Michigan Cancer Center,
Ann Arbor, MI
07 2003 – 06/2006 Fellowship in Hematology/Oncology/BMT, Department of Internal
Medicine, University of Michigan Cancer Center, Ann Arbor, MI

Certification and Licensure

1987 State Medical Council (Russia)
1998 United States Educational Commission for Foreign Medical Graduates
(ECFMG)
2003 State of Michigan Board of Pharmacy #5315016673, expired 1/31/08
2003 Michigan License Regulation #4301074606, expired 1/31/08
2005 Diplomate, American Board of Internal Medicine, Internal Medicine
2006 Diplomate, American Board of Internal Medicine, Medical Oncology
2016 Diplomate, American Board of Internal Medicine, Medical Oncology, re certified
2008 Medical Board of California #A105568, Issuance Date 9/17/08

Academic and Clinical Appointments
Academic appointments:

09/1987 – 12/1990 Research Associate in Pediatric Hematology, Union Research Center of
01/1991 – 09/1995 Senior Scientist at Research Institute of Pediatric Hematology/Oncology,
Moscow, Russia
09/1995 – 06/1999 Research Associate in Pediatrics, DFCI/Harvard Medical School
Hematology, Moscow, Russia
06/2005 – 06/2006 Clinical Lecturer, Internal Medicine, Hematology/Oncology, Blood & Marrow Transplant Program, University of Michigan Cancer Center.
07/2006 – 11/2008 Assistant Professor, Internal Medicine, Hematology/Oncology, Blood& Marrow Transplant Program, University of Michigan Cancer Center.
07/2019 – present Professor, Dmitriy Rogachev National Medical Research Center of Pediatric Hematology/Oncology/Immunology, Department of Hematology & Cellular Therapeutics, Moscow, Russian Federation

Clinical Appointments:

09/1987 – 02/1990 Physician, Pediatric Hematology/Oncology Department, Union Research
Institute of Hematology and Central Republican Children’s Hospital,
Moscow, Russia
03/1991 – 01/1993 Head of Pediatric Bone Marrow Transplantation Service, Research Institute
of Pediatric Hematology/Oncology, Moscow, Russia
02/1993 – 07/ 1995 Chief of Bone Marrow Transplantation Department, Research Institute of
Pediatric Hematology, Ministry of Health of Russia, Moscow, Russia
07/1999 – 07/2001 House Officer, Department of Pathology, University of Michigan and
Veterans’ Administration Hospitals, Ann Arbor, MI
07/2001 – 07/2003 House Officer, Dept. of Internal Medicine, University of Michigan Medical
Center and Veterans’ Administration Hospitals, Ann Arbor, MI
07/2003 – 06/2005 House Officer-Fellow, Division Hematology/Oncology, University of
Michigan Medical Center and Veterans’ Administration Hospitals
06/2005 – 10/2008 Attending physician, Blood & Marrow Transplantation Program,
Internal Medicine, University of Michigan Cancer Center
11/ 2008 – 09/2011 Clinical Director, Alta Bates Summit Blood & Marrow Transplantation Program, 2001 Dwight Way, Berkeley, CA 94704 and 2450 Ashby Avenue, Berkeley, CA 94705
09/2011 - present Medical Director, Malignant Hematology/ Blood & Marrow Transplantation Program, Alta Bates Summit Medical Center, 2001 Dwight Way, Berkeley, CA 94704 and 2450 Ashby Avenue, Berkeley, CA 94705

Principal Investigator Role:

1. A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF LUSPATERCEPT (ACE-536) VERSUS EPOETIN ALFA FOR THE TREATMENT OF ANEMIA DUE TO IPSS-R VERY LOW, LOW OR INTERMEDIATE RISK MYELODYSPLASTIC SYNDROMES (MDS) IN ESA NAÏVE SUBJECTS WHO REQUIRE RED BLOOD CELL TRANSFUSIONS The “COMMANDS” Trial PROTOCOL NUMBER: ACE-536-MDS-002

2. ICL, deferasirox, Exjade Protocol CICL670AUS47 A 2-year, multi-center, Phase II, open-label, fixed-dose, randomized comparative trial of azacitidine, with or without deferasirox in patients with higher risk myelodysplastic syndromes

3. MIDOSTAURIN (PKC412) Study CPKC412AUS56X (4/28/16 to 11/28/18).
An open-label, multi-center, Expanded Treatment Protocol of Midostaurin (PKC412) in adult patients with newly diagnosed Fms-like tyrosine kinase receptor (FLT3) mutated Acute Myeloid Leukemia (AML) who are eligible for standard induction and consolidation

4. INCB-MA-PV-401 TITLE: PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC OR COMMUNITY CLINICAL PRACTICES SHORT TITLE: PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS WITH POLYCYTHEMIA VERA IN US CLINICAL PRACTICES (REVEAL) 11/8/15 to ONGOING (9/1/16 active, closed to enrollment)

5. INCB 18424-362 A Randomized, Double-Blind, Phase 3 Study of the JAK1/2 Inhibitor, Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 1 Study) 9/7/2015 to 5/6/2016

6. A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multicenter Clinical Trial to Study the Safety, Tolerability, Efficacy, and Immunogenicity of V212 in Recipients of Autologous Hematopoietic Cell Transplants (HCTs). PN001
Protocol # MER_V212-001-00

7. Janssen 54767414MMY3008: A Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects with Previously Untreated Multiple Myeloma who are Ineligible for High Dose Therapy 5/14/2015 to 4/12/2016

8. [Protocol #: INCB-MA-MF-401]: Prospective, Longitudinal, Non-Interventional Study of Disease Burden and Treatment of Patients with Low-Risk Myelofibrosis (MF) or High-Risk Essential Thrombocythemia (ET) or ET Patients Receiving ET-Directed Therapy (MOST) 7/19/2017 to ON GOING ET/MF dates vary, active, closed to enrollment

9. Spectrum - SPI-ZEV-11-301 A Phase 3, Open-label, Multicenter, Randomized Study of Sequential Zevalin (Ibritumomab Tiuxetan) Versus Observation in Patients at Least 60 Years of Age With Newly Diagnosed Diffuse Large B-cell Lymphoma in PET-negative Complete Remission After R-CHOP or R-CHOP-like Therapy

HONORS/AWARDS

1985 Medical Diploma cum laude
1990 Gigax Foundation Fellowship Award in Pediatric Oncology, St.-Anna
Kinderspital, Vienna

1996 David Abraham Fellowship Award in Pediatric Oncology, Dana Farber Cancer Institute
1998 American Society of Hematology Meeting Award for the best abstract.
2009 American Society of BMT Meeting Award for the best abstract.

Membership in Professional Societies

1998 American Society of Clinical Pathology
2008 American Society of Hematology
2008 American Society of Bone Marrow Transplantation
2008 American Society of Clinical Oncology

Teaching

1991 – 1995 Lecturer, Postgraduate Courses in Pediatric Hematology/Oncology and
Advanced Hematology and Blood and Marrow Transplantation
Medical University II, Moscow, Russia
1993 –1995 Lecturer, Clinical Seminars for Residents
Central Republican Children’s Hospital, Moscow, Russia
1999 – 2001 Presenter, Blood and Marrow Transplantation and Peripheral Blood Stem Cell Transplantation Education of Blood Bank Staff University of Michigan,
2003 – 2005 Presenter, Internal Medicine House Staff Teaching in Consultative Hematology, Department of Internal Medicine
University of Michigan, Ann Arbor, MI
2005 – 2006 Clinical Lecturer/Instructor, Blood and Marrow Transplantation Program Department of Internal Medicine University of Michigan, Ann Arbor, MI
2006 – 2008 Presenter, Education of Residents and Inpatient Teaching Rounds
University of Michigan, Ann Arbor, MI
2006 – 2008 Assistant Professor in Hematology/Oncology, Blood and Marrow Transplantation Program
University of Michigan Medical School, Ann Arbor, MI
2006 – 2008 Presenter, Fellows’ Didactic Conferences
University of Michigan Medical School, Ann Arbor, MI
2006 – 2008 Mentor, Fellows’ Journal Club Mentorship
University of Michigan Medical School, Ann Arbor, MI
2006 – 2008 Presenter, Education of Nurse Practitioners and Physician’s Assistants
University of Michigan, Ann Arbor, MI
2006 – 2008 M2 Hematology Sequence Lecturer, Small Group Seminars
University of Michigan Medical School, Ann Arbor, MI
2007 – 2008 Supervisor/Content Advisor for Fellow’s Educational Curriculum Development Blood and Marrow Transplantation Program University of Michigan, Ann Arbor, MI.

Committee, Organizational Service

Institutional

09/2007 –11/2008 Morbidity and Mortality Consultant, Blood and Marrow Transplantation Program
University of Michigan, Ann Arbor, MI
01/2012 – 12/2017 Medical Executive Committee of the Alta Bates Medical Center, Berkeley, CA member at large.
11/2008- present Cancer Advisory Committee, Alta Bates Summit Medical Center, member.

Consulting Positions

1991 – 1995 Consultant Adviser for the National Emergency Medicine Services for
Remote Regions of USSR/Russia
1991 – 1996 Consultant of Hematology/Oncology Service in the Central Republican
Children’s Hospital, Moscow, Russia
2009 – present Advisory Boards member for Takeda/Millenium Pharmaceutical
2016 – present Consultant to Amgen/Onyx Pharmaceutical

Extramural Invited Presentations

08/1992 Presenter, International Society of Hematology (ISH) Poster Presentation: “Anemia Fanconi: Features of Oxidative Metabolism (Pathogenesis, Clinical Features, Treatment).” International Society of Hematology (ISH) London, UK

10/1993 Presenter, International Society of Pediatric Oncology (SIOP) 25th Annual Congress Poster Presentation: “Intensive Chemotherapy of Acute Leukemias and Lymphomas in Children with BFM Protocols: Moscow Experience 1990-1992.”
International Society of Pediatric Oncology (SIOP) 25th Annual Congress
San Francisco, CA 10/1994 Presenter, International Society of Pediatric Oncology (SIOP) 26th Annual Congress Poster Presentation: “Treatment of AML in Children with AML-BFM 90 Protocol - Moscow Experience.” International Society of Pediatric Oncology (SIOP) 26th Annual Congress Paris, France
08/1994 Presenter, Annual International Symposium of Hematology/Oncology Educational Program Lecture – St.-Petersburgh’s Nights: “Neuroleukemia in Children: Prevention and Therapy.” St. Petersburg, Russia
02/1995 Presenter, Acute Leukemia V Meeting Poster Presentation: “The Treatment of ALL in Children According to BFM Protocol.” Acute Leukemia V MeetingMunster, Germany
07/1995 Presenter, Lecture: “Treatment of ALL in Children- Interim Results of Moscow-Berlin Clinical Trial and BFM Strategy.” University of Pittsburgh Pittsburg, Pennsylvania
1995 Presenter, Lecture: “Allogeneic BMT for Bone Marrow Failure Syndromes in Children.” Annual Symposium of Moscow’s Society of Pediatrics
Moscow, Russia
12/1997 Presenter, American Society of Hematology 39th Annual Meeting and Exhibition Poster Presentation: “A Peptide Containing Y704 of the G-CSFR Associates with 93kD and 120kD Proteins in G-CSFR-Ba/F3 Cells That Are Inducible (CD11b) in Response to G-CSF.”
American Society of Hematology 39th Annual Meeting and Exhibition
San Diego, CA
12/1998 Presenter, American Society of Hematology 40th Annual Meeting and Exhibition Oral Presentation, Experimental Transplantation Section: “Keratinocyte Growth Factor Separates Graft-Vs-Host Disease from Graft-Vs-Leukemia Effect after Experimental Allogeneic BMT.” American Society of Hematology 40th Annual Meeting and Exhibition Miami, FL
06/13/2006 Presenter, Annual Seminars in Hematology & Stem Cell Transplantation: “CNS Complications of Allogeneic BMT.” St. Petersburg Pavlov State Medical University Meeting St. Petersburg, Russia
03/07/2007 Presenter, Blood and Marrow Transplantation Seminar of Hematology/Oncology: “Proteomics of Acute GVHD.” Beth Israel Hospital Meeting, Boston, MA
03/25/2007 Presenter, European Group for Blood and Marrow Transplantation 33rd Annual Congress Plenary Session Presentation: “Distinctive Plasma Protein Profiles in Patients with Acute Graft-Versus-Host Disease.” Oral presentation.
European Group for Blood and Marrow Transplantation 33rd Annual Congress
Lyon, France
05/22/2007 Presenter, Division of Hematology/Oncology Seminar Series: “Novel Diagnostic and Therapeutic Approaches to Acute GVHD.” Case Western Reserve University Meeting Cleveland, OH
02/06/2009 Presenter, American Society of BMT Meeting Plenary Session Presentation “Rapid immunosuppression taper following reduced intensity HSCT from MRD is tolerable but does not improve outcomes of advanced hematologic malignancies”,
Tampa, FL.
06/01/2015 Presenter, International Work Shop on BMT for Hematologic Malignancies and Autoimmune diseases in Pediatrics at Federal Clinical Research Center for Pediatric Hematology/Oncology & Immunology, Rogachev’s.
“Modulation of GVHD using Histone Deacetylase Inhibitor following Allogeneic HSC Transplantation from Matched Related Donors”. Moscow, Russia.

BIBLIOGRAPHY

Peer-Reviewed Publications

1. Rumiancev AC, Kryzhanovskii OI, Maschan AA. The Pathogenesis and Treatment of the Crush Syndrome in Children. Pediatria 8:87-93, 1991.
2. Maschan AA, Samochatova EV, Kryzhanovskii OI. Tactics of Adjuvant Therapy in the Treatment of Acute Lymphoblastic Leukemia according to the BFM Program. Pediatria 2:68-78, 1992.
3. Krijanovski OI, Lebedev VV, Vladimirskaia EB. Defect in Clonogenic Precursors of Bone Marrow Stromal Fibroblasts in Children Suffering from Diamond-Blackfan Anemia. Pediatric Hematology, Oncology, and Immunology. Fascicles of Research Institute of Pediatric Hematology, ed. Moscow Academy Press: 75-79, 1993.
4. Vladimirskaia EB, Zamarraeva NV, Lebedev VV, Kryzhanovskii OI, Rumiantsev AG, Sallakh S, Tabet S, Mazo IB. The Effect of Polychemotherapy on Hemopoiesis in Acute Lymphoblastic Leukemia in Children. Haematology and Transfusiology (Gematologia I Transfuziologia) 38(5):6-10, May 1993.
5. Lebedev VV, Karachunskii AI, Kryzhanovskii OI, Osokin AG, Rumiantsev AG, Samochatova EV, Belikova Liu, Gorban’ZhI, Kharit Mia, Maschan AA. Comparative Effectiveness of Treatment of Non-Hodgkin’s Lymphoma in Children Using Protocols BFM-90 and Non-Programmed Courses Based on the ACOP Regimen. Haematology and Transfusiology (Gematologia I Transfuziologia) 39(2):25-29, March – April 1994.
6. Rumiantsev AG, Samochatova EV, Zhestkova NM, Zhiganova TV, Karachunskii AI, Kryzhanovskii OI, Maschan AA, Mazo IB, Baidun LV, Bliokh ZhL. Results of Treatment of Acute Leukemia in Children Using Intensive Therapy Programs. Haematology and Transfusiology (Gematologia I Transfuziologia) 39(2):21-25, March – April 1994.
7. Vladimirskaia EB, Aimanbetova AA, Kryzhanovskii OI, Osipova EIu, Zamaraeva NV, Rumiantsev AG. Regulation of Proliferation of Stromal Fibroblasts with Methylprednisolone in Cultures in Vitro. Haematology and Transfusiology (Gematologia I Transfuziologia) 39(2):11-14, March – April 1994.
8. Vladimirskaia EB, Zamarraeva NV, Lebedev VV, Krijanovski OI, et al. Effect of Polychemotherapyon Bone Marrow Granulocyte-Macrophage and Stromal Precursors in Children with ALL. Acute Leukemias IV. Buchner et al., ed. Berlin: Springer-Verlag: 389, 1994.
9. Krijanovski OI, Maschan AA, Vladimirskaia. Allogeneic Bone Marrow Transplantation in Children (The Experience of Pediatric Hematology Research Institute). Perinatologia I Pediatria 1:4-8, 1995.
10. Vladimirskaya E, Zamaraeva N, Osipova E, Volunetz M, Alexeev., Krijanovski OI, Rumiantsev A. The Effect of Methylprednisolone on Bone Marrow and Spleen Clonogenic Fibroblasts in Humans. NATO ASI Series, Vol. H 94. Gene Technology. Springer-Verlug Berlin Heiderberg, 1996.
11. Maschan AA, Krijanovski OI, Yourlove MI, Skorobogatova EV, Pashanov ED, Patapova YE, Timonova LA, Bogacheva NY, Samochatova EV, Rumiantsev AG. Intermediate-Dose Busulfan and Cyclophosphomide as a Conditioning Regimen for Bone Marrow Transplantation in Case of Fanconi Anemia in Myelodysplastic Transformation. Bone Marrow Transplantation 19:385-387, 1997.
12. Jubinsky PT, Krijanovski OI, Nathan DG, Tavernier J, Sieff CA. The Beta Chain of the Interleukin-3 Receptor Functionally Associates with the Erythropoietin Receptor. Blood 90(5):1867-1873, September 1, 1997.
13. Krijanovski OI and Sieff CA. Diamond-Blackfan Anemia. Hematology/Oncology Clinics of North America 11(6):1061-1077, December 1997. Review.
14. Pachanov E, Skorobogatova E, Krijanovski OI, Maschan A. The Possible Way to Decrease of Conditioning Regimen Toxicity in Bone Marrow Transplantation Pediatric Patients. Toxicology Letters 95(1001):74-75(2), 1998.
15. Maschan A, Bogatcheva N, Krijanovski OI, et al. Results at a Single Center of Immunosuppression with Cyclosporine A in 66 Children with Aplastic Anaemia. British Journal of Haematology 106(4):967-970, 1999.
16. Krijanovski OI, Hill GR, Cooke KR, Teshima T, Crawford JM, Brinson YS, Ferrara JL. Keratinocyte Growth Factor Separates Graft-versus-Leukemia Effects from Graft-versus-Host-Disease. Blood 94 (2):825-831, July 15, 1999.
17. Hill GR, Teshima T, Rebel VI, Krijanovski OI, Cooke KR, Brinson YS, Ferrara JLM. The p55 TNF-Alpha Receptor Plays a Critical Role in T Cell Alloreactivity. Journal of Immunology 164(2):656-663, January 15, 2000.
18. Reddy P, Maeda Y, Liu C, Krijanovski OI, Korngold R, Ferrara JLM. A Crucial Role for Antigen-Presenting Cells and Alloantigen Expression in Graft-versus-Leukemia Responses. Nature Medicine, 11: 1244-9, 2005.
19. Levine JE, Paczesny S, Mineishi S, Braun T, Choi SW, Hutchinson RJ, Jones D, Khaled Y, Kitko CL, Bickley D, Krijanovski O, Reddy P, Yanik G, Ferrara JL. Etanercept Plus Methylprednisolone as Initial Therapy for Acute GVHD. Blood 111(4):2470-2475, February 15 2008, EPub November 27, 2007.
20. Peres E, Levine J, Kato K, Krijanovski O, Khaled Y, Ferrara J, Yanik G, Mineishi S. Reduced Intensity Versus Full Myeloablative Stem Cell Transplant for Advanced Chronic Lymphocytic Leukemia. Biology of Blood and Marrow Transplantation 14(2): 62, February 2008.
21. Kato K, Krijanovski O, Khaled Y, Peres E, Reddy P, Choi S, Kitko C, Yanik G, Levine J, Ferrara J, Mineishi S. Allogeneic Hematopoietic Stem Cell Transplantation has Curative Potential for Chemorefractory Non-Hodgkin Lymphoma. Biology of Blood and Marrow Transplantation 14(2): 63-64, February 2008.
22. Reddy P, Sun Y, Toubai T, Duran-Struuck R, Clouthier SG, Weisiger E, Maeda Y, Tawara I, Krijanovski O, Gatza E, Liu C, Malter C, Mascagni P, Dinarello CA, Ferrara JL. Histone Deacetylase Inhibition Modulates Indoleamine 2,3-Dioxygenase-Dependent DC Functions and Regulates Experimental Graft-Versus-Host Disease in Mice. Journal of Clinical Investigation 118(7): 2562-2573, July 1, 2008.
23. Krijanovski O, Paczesny S, Braun T, Choi S, Clouthier S, Kuick R, Misek D, Cooke K, Kitko C, Weyand A, Bickley D, Jones D, Whitfield J, Reddy P, Levine J, Hanash S, Ferrara JLM. A Biomarker Panel for Acute Graft Versus Host Disease. Blood, 2009.
24. Peres E, Braun T, Krijanovski O, Khaled Y, Levine JE, Yanik G, Kato K, Mineishi S. Reduced intensity versus full myeloablative stem cell transplant for advanced CLL. Bone Marrow Transplant. 2009 Mar 23.
25. Peres E, Levine JE, Khaled YA, Ibrahim RB, Braun TM, Krijanovski OI, Mineishi S, Abidi MH. Cardiac complications in patients undergoing a reduced-intensity conditioning hematopoietic stem cell transplantation Bone Marrow Transplant. 2009 May 25.
26. Khaled Y, Reddy P, Krijanovski O. Emerging drugs for acute graft-versus-host disease. Expert Opin Emerg Drugs. 2009 Jun;14(2):219-32.
27. Choi SW, Braun T, Chang L, Ferrara JL, Pawarode A, Magenau JM, Hou G, Beumer JH, Levine JE, Goldstein S, Couriel DR, Stockerl-Goldstein K, Krijanovski OI, Kitko C, Yanik GA, Lehmann MH, Tawara I, Sun Y, Paczesny S, Mapara MY, Dinarello CA, DiPersio JF, Reddy P. Vorinostat plus tacrolimus and mycophenolate to prevent graft-versus-host disease after related-donor reduced-intensity conditioning allogeneic haemopoietic stem-cell transplantation: a phase 1/2 trial. Lancet Oncol. 2014 Jan;15(1):87-95. doi: 10.1016/S1470-2045(13)70512-6. Epub 2013 Nov 30.
28. Waller EK, Logan BR, Harris WA, Devine SM, Porter DL, Mineishi S, McCarty JM, Gonzalez.CE, Spitzer TR, Krijanovski OI, Linenberger ML, Woolfrey A, Howard A, Wu J, Confer DL, Anasetti C. Improved Survival After Transplantation of More Donor Plasmacytoid Dendritic or Naïve T Cells From Unrelated-Donor Marrow Grafts: Results From BMTCTN 0201. J Clin Oncol. 2014 Aug 1;32(22):2365-72. doi: 10.1200/JCO.2013.54.4577. Epub 2014 Jun 30.

Book Chapters

1. Krijanovski OI and Miagkova NM. Recent Advances and Current Management of AML in Adults. Chapter: “Supportive Care in Hematology/Oncology,” Academic Press, Moscow, 2007.

Abstracts

1. Samochatova EV, Maschan AA, Korkina LG, Krijanovski OI, Anemia Fanconi: Features of Oxidative Metabolism (Pathogenesis, Clinical Features, Treatment). Blood, Suppl.,1992.

2. Samochatova EV, Rumiancev AG, Krijanovski OI, Karachunsky AI, et al. Intensive Chemotherapy in Children with BFM Protocols: Moscow Experience 1990-1992. First Success and Failures. Annals of Hematology, Suppl.2-A80, 1992.

3. Maschan AA, Samochatova EV, Karachunski AI, Krijanovski OI et.al. Treatment of AML in Children with AML-BFM 90 Protocol - Moscow Experience. International Society of Pediatric Oncology (SIOP) 26th Annual Congress, Poster Presentation, October 1994, Paris, France, Annals of Hematology Suppl.II Vol.70, 1995.

4. Dubrovina EA, Samochatova EV, Krijanovski OI, et al. Acute Myeloblastic Leukemia with t(8;21) Translocation Associated with Granulocytic Sarcoma. Annals of Hematology, Suppl.II Vol.70 A115, 1995.

5. Samochatova E., Karachunski A., Krijanovski OI, Maschan A., Zhestkova N., Baydun A., Rumyantcev A. Acute Leukemia V Meeting Poster Presentation: The Treatment of Acute Lymphoblastic Leukemia in Children According to BFM Protocol. Acute Leukemia V Meeting, Poster Presentation, Munster, Germany, February 1995, NATO ASI Series, Vol. H 94. Gene Technology. Springer-Verlug Berlin Heiderberg, 1996.

6. Krijanovski OI and Sieff CA. A Peptide Containing Y704 of the G-CSFR Associates with 93kD and 120kD Proteins in G-CSFR-Ba/F3 Cells That Are Inducible (CD11b) in Response to G-CSF. American Society of Hematology 39th Annual Meeting and Exhibition, Blood 190(10) Suppl.1:1392, 1997.

7. Reddy P, Maeda Y, Duran-Struuck R, Krijanovski O, Dinarello C, Ferrara JL. Histone Deacetylase Inhibitors Induce Immuno-Dominant Suppression of Dendritic Cells. American Society of Hematology 47th Annual Meeting and Exhibition, Session Type: Oral Session, December 11, 2005, Atlanta, GA, Abstract #456, Blood 106: 456, November 2005.

8. Levine JE, Kitko C, Yanik G, Braun T, Paczesny S, Mineishi S, Krijanovski OI, Jones D, Cooke KR, Whitfield J, Hutchinson RJ, and Ferrara JLM. Changes in TNFR1 Levels in the First Week Post-Myeloablative HSCT Correlate with Severity and Incidence of GVHD and 1y TRM. American Society of Hematology 48th Annual Meeting and Exhibition, Session Type: Oral Session, December 11, 2006, Orlando, FL, Abstract #37, Blood 108(11): 37, November 16, 2006.

9. Levine JE, Yanik GA, Cooke KR, Reddy P, Hutchinson R, Krijanovski O, McMahon C, Whitfield J, Ferrara JL. Elevated TNF Receptor Levels Early after Myeloablative BMT Predict for GVHD and Death. American Society for Blood and Marrow Transplantation Tandem Meeting, Poster Presentation, Abstract, Honolulu, HI, February 17, 2006. Biology of Blood and Marrow Transplantation 12(2): 50, February 2006.

10. Krijanovski O, Paczesny S, Clouthier SG, Kuick R, Misek DE, Levine JE, Cooke KR, Hanash SM, Ferrara JLM. Distinctive Plasma Protein Profiles in Patients with Acute Graft-Versus-Host Disease. European Group for Blood and Marrow Transplantation 33rd Annual Congress, Plenary Session Presentation, Abstract O284,Lyon, France, March 25, 2007, Bone Marrow Transplantation 39 (S1 , S26), April 2007.

11. Khaled Y, Kato K, Levine JE, Mellacheruvu S, Jakubowiak A, Krijanovski O, Peres E, Reddy P, Knott K, Yanik G, Ferrara JLM, Mineishi S. Superior Long Term Progression Free Survival of Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma Compared to Autologous Hematopoietic Stem Cell Transplantation after Identical Conditioning Regimen. American Society of Hematology 49th Annual Meeting and Exhibition, Session Type: Poster Session III, December 10, 2007, Atlanta, GA, Abstract #3031, Blood 110(11): 3031, November 16, 2007.

12. Levine JE, Paczesny S, Mineishi S, Braun T, Choi SW, Hutchinson RJ, Jones D, Khaled Y, Kitko C, Krijanovski O, Reddy P, Yanik G, Ferrara JLM. Etanercept Plus Methylprednisolone as Initial Therapy for Acute GVHD. American Society of Hematology 49th Annual Meeting and Exhibition, Session Type: Oral Session, Atlanta, GA, Abstract #39, Blood 110(11): 39, November 16, 2007.

13. Paczesny S, Choi S, Braun T, Kitko C, Krijanovski O, Clouthier S, Weyand A, Bickley D, Jones D, Levine JE, Ferrara JL. A Four Protein Plasma Fingerprint of Acute Graft Versus Host Disease Predicts Long Term Survival. American Society of Hematology 49th Annual Meeting and Exhibition, Session Type: Oral Session, December 9, 2007, Atlanta, GA, Abstract #38, Blood 110(11): 38, November 16, 2007.

14. Kato K, Krijanovski O, Khaled Y, Peres E, Reddy P, Choi S, Kitko C, Yanik G, Levine JE, Ferrara JLM, Mineishi S. Allogeneic Hematopoietic Stem Cell Transplantation Has Curative Potential for Chemorefractory Non-Hodgkin Lymphoma. American Society for Blood and Marrow Transplantation Tandem Meetings, Abstract #171, San Diego, CA, February 2008. Biology of Blood and Marrow Transplantation 14(2): 63-64, February 2008.

15. Joseph Maslak, Daniel Kaul, MD, James Connelly, MD, Shin Mineishi, MD, John E. Levine, MD, Edward M. Peres, MD, Carrie Kitko, MD, Sung W. Choi, MD, Yasser Khaled, MD, Oleg I. Krijanovski, PhD, MD, Stefanie Digiandomenico, Eric White, MD, Thomas Braun, PhD, Pavan Reddy, MD, Attaphol Pawarode, MD, James L.M. Ferrara, MD, Gregory A. Yanik, MD. Bronchoscopic Evaluation of Pulmonary Complications in Patients Undergoing Reduced-Intensity Versus Full-Intensity Transplants. Blood (2008) 112 (11): 2163.

16. Shin Mineishi, MD, John Magenau, MD, Attaphol Pawarode, MD, Timothy Buck, Dawn Jones, RN, Koji Kato, MD, David Frame, Pharm.D, Lisa Kujawski, MD, Harry Paul Erba, MD, PhD, Yasser Khaled, MD, Edward M. Peres, MD, Oleg I. Krijanovski, PhD, MD, Pavan Reddy, MD, Carrie Kitko, MD, Sung Choi, MD, Gregory A. Yanik, MD, Thomas Braun, PhD, James L.M. Ferrara, MD, John E. Levine, MD, Myeloablative Conditioning with Clofarabine and Busulfan X 4 (CloBu4) Is Well Tolerated, Facilitates Secure Engraftment, and Exhibits Significant Anti-Tumor Activity against Non-Remission Hematologic Malignancies Including AML. Blood (2008) 112 (11): 2150.

17. Sophie Paczesny, MD, PhD., John E. Levine, MD, Jason Hogan, PhD., Jeffrey Crawford, Thomas Braun, PhD, Hong Wang, PhD., Vitor Faca, PhD, Qing Zhang, Sharon Pitteri, PHD, Alice Chin, Sung Choi, MD, Carrie Kitko, MD, Oleg I. Krijanovski, PhD, MD, Pavan Reddy, MD, Shin Mineishi, MD, Joel Whitfield, Dawn Jones, RN, Samir Hanash, MD, PhD, James L.M. Ferrara, MD. Elafin Is a Biomarker of Graft Versus Host Disease of the Skin. Blood (2008) 112 (11): 716.

18. Krijanovski, O, Krijanovski, Y, Khaled, Y, Cummings, T, Braun, T, Reddy, P, Peres, E, Mineishi, S, Kitko, C, Choi, S, Yanik, G, Pawarode, A, Paczesny, S, Levine, JE Rapid Immunosupression Taper Following Reduced Intensity HSCT From MRD Is Tolerable But Does Not Improve Outcomes of Advanced Hematologic Malignancies. Biology of Blood and Marrow Transplantation, 15(2): 6-7, 2009

19. Vladimir I. Vorobyev, MD PhD, Vera A. Zherebtsova, MD PhD, Egor I. Dubrovin, Liudmila A. Bychenkova, Lev S. Butaev, Larisa A. Muha, Yulia B. Kochkareva, Valentina L. Ivanova, Eugene A. Nikitin, MD PhD Professor, Gayane Tumyan, DMSc, MD PhD, Vadim A Doronin, MD, Oleg I. Krijanovski, MD PhD, Vadim Ptushkin, MD PhD.
Ibrutinib Monotherapy in Patients with Relapsed/Refractory Mantle Cell Lymphoma in Community Clinical Practice Outside of Clinical Trials. Blood (2019) 134 (Supplement_1): 5255.

Membership in Editorial Boards of Scientific Peer-Reviewed Journals:

“Russian Journal of Hematology & Transfusiology” (Gematologiya i Transfuziologiya, Scopus, DOI 10.35754).